Scilex计划向林业发展局申请核准,以扩大使用其非类阿片止痛缓解器ELYXYB,用于急性疼痛。 Scilex plans to file for FDA approval to expand use of its non-opioid pain reliever, ELYXYB, for acute pain.

Scilex Holding Company计划向林业发展局提交一种补充性新药物应用(SNDA),用于ELYXYB,一种Celecoxib配方,旨在将其使用扩大到急性疼痛。 Scilex Holding Company plans to file a Supplemental New Drug Application (sNDA) with the FDA for ELYXYB, a Celecoxib formulation, aiming to expand its use to acute pain. ELYXYB是一种非类阿片替代品,旨在迅速和持久地减轻疼痛,有可能减少对类阿片的依赖。 ELYXYB is a non-opioid alternative designed for rapid and lasting pain relief, potentially reducing reliance on opioids. 此举的目标是建立30亿美元的市场,并遵循积极的临床试验结果,显示大幅度减轻疼痛和病人满意度。 The move targets a $3 billion market and follows positive clinical trial results showing significant pain reduction and patient satisfaction.